Phase 1 Eczema Trial, Recruiting NCT07527923 Sponsor: Regeneron Pharmaceuticals Condition: Eczema
Back to Eczema

Phase 1 Eczema Trial, Recruiting

NCT07527923
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Part A (Healthy Volunteers):

  • You are considered to be in good general health, based on your medical history, physical check-up, and test results at the start of the study
  • Your Body Mass Index (BMI — a measure of body weight relative to height) is between 18 and 31 at the start of the study

Part B (Atopic Dermatitis Patients):

  • You have had atopic dermatitis (eczema) for at least 6 months before joining the study
  • Your eczema severity score (called EASI) is 5 or above at both your initial and baseline appointments (confirm with trial site)
  • Your overall skin condition rating (called IGA) is 2 or above at both your initial and baseline appointments (confirm with trial site)

Who may not be able to join:

Part A (Healthy Volunteers):

  • You were admitted to hospital for more than 24 hours for any reason within the 30 days before your first appointment
  • You have a known allergy or sensitivity to the study treatment or any of its ingredients
  • You have a history of a parasitic infection, except for trichomoniasis that has been fully treated
  • You received a live vaccine within 1 month before your first appointment, or expect to need one during the study
  • You have a history of alcohol or drug misuse, as judged by the study doctor

Part B (Atopic Dermatitis Patients):

  • You have a known or suspected history of a weakened immune system
  • You have other skin conditions that could affect how the study results are measured
  • You are unable to stop certain medications or treatments before and during the study, as outlined by the study rules (confirm with trial site)
  • You have an ongoing long-term health condition that is not well controlled and may require short courses of steroid tablets during the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Clinical Trial Management, Regeneron Pharmaceuticals

Phone: 844-734-6643

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Regeneron Pharmaceuticals
Registry
ClinicalTrials.gov
Start date
22 May 2026
Est. completion
23 June 2028

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Occurrence of Treatment Emergent Adverse Events (TEAEs); Severity of TEAEs

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov